SRDX - Surmodics Non-GAAP EPS of -$0.34 beats by $0.04 revenue of $24.9M misses by $0.29M

• Surmodics press release ( NASDAQ: SRDX ): Q3 Non-GAAP EPS of -$0.34 beats by $0.04 .
• Revenue of $24.9M (+4.2% Y/Y) misses by $0.29M .
• Surmodics reported cash and investments totaling $22.1 million and $10 million in outstanding borrowings on its $25 million line of credit. Surmodics reported $3.5 million of cash used in operating activities and $0.9 million in capital expenditures for the third quarter of fiscal 2022.
• Surmodics expects full year fiscal 2022 revenue to range from $97 million to $99 million, from the previous range of $98 million to $101 million.

• Company’s strategy, to a range from a loss per share of $(1.50) to $(1.35), from the previous range of $(1.70) to $(1.35). Non-GAAP diluted EPS for fiscal 2022 is expected to range from a loss per share of $(1.23) to $(1.08).

For further details see: